Adisseo,Novozymes Enter Partnership in Probiotics for Animals
News Jun 01, 2015
Adisseo and Novozymes, two global leaders in the animal nutrition and feed additive industry, today announced a partnership to develop and market a probiotic for poultry. Novozymes will be responsible for in-vitro screening, development and production, while Adisseo will manage in-vivo testing, marketing and sales. The partners expect to launch the product within the next 12 months.
“The world needs new solutions to feed a growing global population in a sustainable way. We are developing a probiotic that can help farmers meet that need,” says Helle Warrer Poulsen, Vice President of Animal Health & Nutrition at Novozymes. “We are excited to partner with Adisseo, who shares our vision of bringing innovation and science to the field of probiotics and offers great expertise and capabilities in feed additives. It is a promising new area for Novozymes where we can leverage our know-how in microbiology, fermentation and animal feed.”
“Innovation is part of Adisseo’s DNA and we are constantly investing, either organically or through strategic partnerships, in new solutions to help our customers optimize livestock performance while reducing environmental impact,” says Jean-Marc Dublanc, CEO of Adisseo. “The decision to enlarge our specialty portfolio with probiotics was therefore a natural one, as was the choice of Novozymes as our partner.”
For decades, antibiotics have been widely used in animal production to help livestock grow, but more and more countries are now banning non-medicinal use as part of strategies to tackle resistance to antibiotic treatments in humans. Consumer-driven curbs on the use of antibiotics as growth promoters have further increased the demand for sustainable alternatives in animal farming.
Probiotics are naturally-occurring live microbes added to feed to improve the gut flora of pigs, poultry and other animals. They improve animal growth and feed utilization and have associated health benefits, thereby providing a natural alternative to antibiotic growth promoters.
Novozymes and Adisseo’s new product will be based on beneficial bacteria that promote weight gain and limit development of unwanted bacteria in the animal’s digestive tract. By using the product, farmers will better control gut health of their animals and achieve an improved feed conversion, meaning less feed consumed to raise an animal. The product will be tailored for poultry, while the partners will explore future opportunities to expand into probiotics for both poultry and swine.
The partnership brings together global players with a solid track record in developing high performance feed additives who share an ambition to enter and develop the market for probiotics. Novozymes will leverage its technology base, proven in enzymes and microbes, and Adisseo brings a unique expertise in amino acids, vitamins, feed enzymes and other feed solutions.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.